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Abstract
Background Human papillomavirus (HPV) vaccination rates among adolescents are increasing in Minnesota (MN) but
remain below the Healthy People 2020 goal of 80% completion of the series. The goal of this study was to identify messaging and interventions impacting HPV vaccine uptake in MN through interviews with clinicians and key stakeholders.
Methods We conducted semi-structured key participant interviews with providers and stakeholders involved in HPV vaccination efforts in MN between 2018 and 2019. Provider interview questions focused on messaging around the HPV vaccine
and clinic-based strategies to impact HPV vaccine uptake. Stakeholder interview questions focused on barriers and facilitators at the organizational or state level, as well as initiatives and collaborations to increase HPV vaccination. Responses to
interviews were recorded and transcribed. Thematic content analysis was used to identify themes from interviews.
Results 14 clinicians and 13 stakeholders were interviewed. Identified themes were grouped into 2 major categories that dealt
with messaging around the HPV vaccine, direct patient–clinician interactions and external messaging, and a third thematic
category involving healthcare system-related factors and interventions. The messaging strategy identified as most useful
was promoting the HPV vaccine for cancer prevention. The need for stakeholders to prioritize HPV vaccination uptake was
identified as a key factor to increasing HPV vaccination rates. Multiple providers and stakeholders identified misinformation
spread through social media as a barrier to HPV vaccine uptake.
Conclusion Emphasizing the HPV vaccine’s cancer prevention benefits and prioritizing it among healthcare stakeholders
were the most consistently cited strategies for promoting HPV vaccine uptake. Methods to combat the negative influence of
misinformation about HPV vaccines in social media are an urgent priority.
Keywords Human papillomavirus · Vaccines · Cancer prevention · Social media
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The HPV vaccine is recommended for administration to all
adolescents in the USA for the prevention of HPV-related
cancers and anogenital warts [1]. Uptake of the HPV vaccine in the USA has been lower than that of other adolescent
vaccines and remains below the Healthy People 2020 goal
of 80% completion of the vaccine series [2]. HPV vaccine
uptake rates also vary regionally and by state. In Minnesota,
data from the Minnesota Department of Health (MDH) indicate that the rate of uptake of the HPV vaccine among adolescents aged 13 to 17 in 2018 was 76.7% for one dose and
58.1% for completion of the series [3]. While these uptake
rates compared favorably to the USA as a whole (68.1% for
receipt of at least one dose and 51.1% for completion of the
series), they remain below the Healthy People 2020 goal [3].
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Clinician recommendations influence parents’ opinion of
their adolescents’ receipt of the HPV vaccine [4, 5]. Multiple
studies have linked a clinician’s recommendation to vaccinate adolescents for HPV to greater willingness to follow
through with vaccination. Clinicians play an important role
in ensuring that adolescents receive the HPV vaccine [4,
5]. Given their importance in discussing the HPV vaccine
with adolescents and their parents, prior efforts have been
made to assess clinicians’ opinions about prioritizing HPV
vaccine delivery, structuring care teams to optimize vaccination efforts, and addressing barriers to vaccination [6].
There are also ongoing efforts to evaluate educational interventions targeted at clinicians to promote HPV vaccination
[7]. Key stakeholders involved in HPV vaccination, such
as those responsible for quality improvement initiatives at
health maintenance organizations or affiliated with local and
state health departments, can also play a role in supporting
HPV vaccination.
In order to better understand what methods to employ to
improve HPV vaccine uptake, we aimed to first understand
what messages were perceived by clinicians and healthcare
stakeholders that were thought to impact uptake of the HPV
vaccine. Additionally, we aimed to gather further knowledge
of best practices and innovative strategies being used to promote HPV vaccine uptake that would provide information to
design future interventions. We performed a thematic content analysis of interviews conducted with practicing clinicians and HPV-focused stakeholders in Minnesota to address
these aims.

Materials and methods
We conducted semi-structured key participant interviews
with 14 clinicians and 13 key stakeholders in Minnesota
regarding HPV vaccination. The interviews took place from
July 2018 to August 2019. Clinicians were interviewed by
an infectious disease fellow physician and PhD student in
epidemiology. Stakeholder interviews were conducted by
an Epidemiology PhD and the project’s principal investigator as well as a PhD student in epidemiology. We asked
about effective messaging strategies, quality improvement
initiatives, and support for HPV vaccine-related legislation
in Minnesota. This research was considered exempt by the
University of Minnesota Institutional Review Board (IRB).
Key informant interviews were structured according to
a guide comprised of questions asked of each clinician or
stakeholder. Clinician and stakeholder interview questions
were developed by a team consisting of an epidemiologist
with experience involving development of HPV screening
guidelines, other epidemiologists with experience conducting content analysis, and a practicing infectious disease
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fellow physician. All interviews were audio recorded and
transcribed verbatim by study personnel.
Thematic content analysis was used to analyze the data.
The framework for content analysis was to identify key
phrases involving messaging around the HPV vaccine and
strategies to improve uptake among clinicians and healthcare-related stakeholders. Prior to conducting interviews,
the coding scheme for clinician interviews was developed
by an infectious disease fellow physician and MPH student
based around pre-determined interview questions. The
coding scheme for stakeholder interviews was developed
by the project’s principal investigator.
The content of the transcribed interviews was independently reviewed by two researchers. Each reviewer first
independently read through the entire text of each transcribed interview once and identified key words or phrases
associated with barriers or facilitators to HPV vaccination. Subsequently, the key words and phrases that were
identified were compared between the two researchers via
a second read-through of each interview with patterns
among the coded words used to identify specific themes.
Identified themes were reviewed in research team sessions
to further refine them and lessen the risk of individual
reader bias.

Clinicians
A target sample size of fifteen individuals was set prior to
clinician recruitment. Clinicians were included if they were
physicians or nurse practitioners currently working in an
ambulatory clinic in Minnesota and were involved in discussions about the HPV vaccine with their patients. Additionally, only clinicians who were able to order and prescribe the
HPV vaccine were eligible to participate. Retired clinicians
and those not actively engaged in an ambulatory primary
care practice were excluded. Affiliates at the Minnesota
chapter of the American Cancer Society and the Minnesota
Department of Health aided in identifying clinicians for this
study through purposive sampling. Outreach to clinicians
occurred via e-mail contact by a research assistant. Potential participants were e-mailed the interview questions and
a consent form prior to the interview. Consent to participate
was confirmed via an e-mail reply message or verbally prior
to the start of the interview.
Participants were asked a series of open-ended questions
related to their communication about the HPV vaccine as
shown in Table 1. Topics that were addressed included concerns related to receipt of the HPV vaccine, differences in
messaging strategies used for different sexes and population subgroups, and quality improvement projects aimed at
increasing uptake of the HPV vaccine within each clinician’s
specific healthcare setting.
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Table 1  Clinician interview questions
1. What are the most common questions or concerns that you have received from patients and their parents about the HPV vaccine? Which concern is the most challenging to address in your opinion?
2. When you encounter concerns about the HPV vaccine in clinic? How do you respond?
3. How often do time pressures during clinic visits impact your ability to discuss the HPV vaccine with patients and their parents/guardians?
4. What strategies have you or your clinic used to ensure that patients return for additional doses of the HPV vaccine in a timely manner?
5. Are there any differences in messages that you use to promote the HPV vaccine for boys vs. girls?
6. Are there any specific populations in your clinic to whom you tailor your messages about the HPV vaccine in a specific way? If so, please
specify how your messaging differs for these groups
7. Has your clinic implemented any quality improvement projects aimed at improving uptake of the HPV vaccine? If so, please describe them
8. What do you think is the most effective strategy for increasing the rate of uptake of the HPV vaccine in your clinic?
9. Is there anything else that you would like to tell us about your experience with promoting the HPV vaccine?

Stakeholders
We also interviewed thirteen key healthcare stakeholders
operating in Minnesota who were identified via purposive
sampling. Identification of stakeholders was achieved with
the assistance of the Minnesota Health Department and the
Minnesota Chapter of the American Cancer Society. Outreach to stakeholders occurred in the same manner as was
done with clinicians.
Participants were asked a series of open-ended questions
adapted from a previously published survey (Table 2) [8].
Questions were asked about facilitators for and barriers to
receipt of HPV vaccination in Minnesota, perceptions about
HPV vaccination at the organizational level, and HPV vaccination collaborations with stakeholders from across the
state. Stakeholders were also asked about possible next steps
for legislation to help improve HPV vaccine uptake rates
statewide.

Results
A total of 27 semi-structured interviews were completed
with 14 clinicians and 13 stakeholders. Upon completion of
content analysis, we identified three larger thematic categories addressing messaging and interventions impacting HPV
vaccine uptake. These three thematic categories included
messaging pertaining to patient–clinician interactions
around the HPV vaccine (Table 3), concerns around external messaging sources not involving direct patient–clinician
interactions (Table 4), and interventions related to healthcare
system-related factors (Table 5).

Patient–clinician interactions
Concerns regarding parental perceptions about the connection between the HPV vaccine and sexual activity featured
commonly in both clinician and stakeholder interviews.
Messaging around the impact of the HPV vaccine on sexual

activity was the most frequently identified theme (for clinicians n = 11, for stakeholders n = 6). Interviewees often cited
how parents would raise concerns that receipt of the HPV
vaccine could result in early initiation of sexual activity and
more frequent sexual encounters among adolescents. As one
clinician expressed, “the parents have to [give] written consent in order to administer [the] HPV vaccine. And I would
say the most common concern is about sexually transmitted virus [sic]. That’s why parents refuse it…” (Clinician
7). One stakeholder noted that “in my opinion, some of it
is perception about, you know, you only need the vaccine
if you are sexually active, and you are going to encourage
sexually active behavior if you give your kid the HPV vaccine” (Stakeholder 2). Concerns that the age at which the
vaccine was recommended was too young were noted by
some clinicians and were related to concerns about addressing adolescent sexual activity— “Addressing the fact that
you are offering a vaccine prior to sexual activity to young
people starting at the age of eleven. That often takes parents
aback quite a bit” (Clinician 9).
Clinicians often also described fielding concerns from
parents of adolescent patients about the safety of the HPV
vaccine. Safety issues primarily came up around the idea that
the vaccine may cause adverse side effects with one clinician noting “I get a lot of questions about side effects, ‘I’ve
heard bad things’ or ‘I’ve heard that a child has fainted’ or
something like that” (Clinician 3).

Influence of external messaging
Discussing vaccines in the context of cancer prevention
was commonly cited as a messaging tool for promotion
of the HPV vaccine (Table 4). Clinicians expressed how a
focus on the benefits of cancer prevention from the HPV
vaccine could turn the focus of patients’ parents away
from concerns about sexual activity. “I think the concern
about cancer and transmission rings home” (Clinician 7).
This was the most utilized method of messaging strategy
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Table 2  Stakeholder Questions (adapted from Cartmell et al., Papillomavirus Res 2018;5:21–31)
Perceptions about barriers and facilitators to HPV vaccination at the state level
1. What factors in our state facilitate HPV vaccination?
2. What are the barriers to HPV vaccination in our state?
3. You mentioned different barriers to HPV vaccination in our state. Thinking about these barriers, what type of strategy or strategies do you
think would be most effective for improving HPV vaccination rates in our state?
4. Are you aware of any vaccination strategies that been used to improve vaccination rates in specific subgroups within the state of Minnesota?
By specific subgroups we mean rural populations, immigrants, specific racial or ethnic groups, LGBTQ youth or young adults or boys only
5. When you think of the health outcomes that an HPV vaccination program is aimed at reducing, what are those health outcomes?
Perceptions about HPV vaccination at the organization level
1. What is your organization’s HPV vaccination coverage rate for the following: Adolescents aged 9 to 10 years? 11 to 14 years? 15 + ?
2. What is the range of HPV vaccination coverage for adolescents among the clinics in your system?
Are you able to determine HPV vaccination rates at the provider level? If yes, do you use this information to work with your providers to
improve HPV vaccination rates?
3. To what extent is improving HPV vaccination rates a priority for your organization?
4. Can you tell me about any quality improvement initiatives or strategies that you have in place for HPV vaccination? What are your thoughts
about the effectiveness of this/these initiatives in increasing HPV vaccination in your organization?
Public health immunization program
1. What impact do you feel that the statewide immunization registry has on HPV vaccination in our state?
2. How do you feel that the state vaccination program influences HPV vaccination in our state?
3. Have you heard about the Minnesota Department of Health Assessment, Feedback, Incentives, and eXchange (AFIX) or enhanced AFIX?
If yes, what impact do you think these programs have on HPV vaccination rates in our state and if applicable on your organization’s HPV
vaccination rates?
4. What else about the public health immunization program and HPV vaccination is important for us to know?
HPV vaccination linkages with statewide stakeholders:
1. Tell me about any collaboration that you’ve been involved with to improve HPV vaccination in the state, and briefly assess the effectiveness
of the collaboration in accomplishing this goal
2. Who do you think are the key stakeholders who should be included in developing strategies to maximize HPV vaccination rates?
Legislation
1. Do you think we need any legislation to improve vaccination rates in our state and if so, what type of legislation do you think is needed?
2. Do you think any specific legislation is needed for HPV vaccines in particular? If yes, what type of legislation do you think is needed?
3. What types of legislation do you think our state legislators would support?
Final Question What else about HPV vaccination is important for us to know?

among all clinicians interviewed (n = 11) and a primary
health outcome of HPV vaccination programs identified
by stakeholders (n = 13).
Concerns surrounding misinformation being spread on
social media were also very common. Clinicians described
encounters with parents who found misinformation online
and how challenging they found addressing misinformation
about the vaccine could be. One clinician noted that misinformation derived from the internet could raise “emotional
kinds of concerns that are really hyped up … It’s pretty
intense. If you bought into it, you’d but into it hook, line, and
sinker. It’s got a lot of fear-based drive to it” (Clinician 10).
Stakeholders shared in this frustration but highlighted that
some media campaigns to raise awareness have had positive
results. As one stakeholder noted, “one way to engage in
this information sharing is through social media usage, with
newspaper articles, mainstream media, and credible news
sources to leverage this information and make vaccination
the norm” (Stakeholder 9).
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Bringing in outside experiences during clinician–patient
interactions was frequently noted as a method to help normalize the HPV vaccine and its benefits and counter misinformation derived from other sources. Some providers
shared their positive personal experiences with the vaccine
as one clinician noted that “I typically share that my children have gotten or will get it and that it’s our only vaccine
that prevents cancer” (Clinician 10). Most clinicians noted
the impact of making a strong recommendation to get the
HPV vaccine as a priority to increase its uptake. As one
clinician stated, “I think having a conversation with the
families to make sure they understand why we’re doing
it and the importance of it—the clinician-to-family conversation. We also present it as part of the recommended
immunization series, but to use, it’s the same … It’s an
important vaccine that we highly recommend” (Clinician
8).

Definition

Text describing parents asking providers if their child is too young
to receive the vaccine
Text describing parental concerns about their child becoming promiscuous or engaging in early sexual activity

Text describing concerns about vaccine safety or side effects (i.e.,
fainting, pain, etc.)
Text describing the importance of provider communication to
patients and parents

Text describing how adolescent patient opinions factor into whether
or not they are vaccinated, addressing adolescent concerns

Recommended age is too young

Sexual Activity

Vaccine side effects and safety

Clinician–patient (Parent) communication

Adolescent opinions

Lack of knowledge/Awareness of the HPV Vaccine Text describing parental lack of knowledge or awareness of HPV
and the HPV vaccine

Theme

Table 3  Patient–Clinician Themes around HPV Vaccination

I think there is also… more education that needs to be out there for
boys needing the vaccine because I think that is fairly new. (Stakeholder 11)
Addressing the fact that you are offering a vaccine prior to sexual
activity to young people starting at the age of eleven. That often
takes parents aback quite a bit. (Clinician 9)
The main concern patients had – one is the way we introduced HPV
when we did it – that it is, you know, a vaccine which prevents STIs.
Some of them really didn’t want to give it to their children because
they perceived it as, you know, it’s going to make them more promiscuous. They are going to become sexually active… (Clinician 4)
I get a lot of questions about side effects, ‘I’ve heard bad things’ or
‘I’ve heard that a child has fainted’ or something like that… (Clinician 3)
At the clinic in the provider’s office, providers are still not giving a
strong recommendation for HPV vaccine, assuming that the HPV
would be a point of controversy with parents. There is very little
reassurance, and providers should be making that presumptive
recommendation and be more comfortable reassuring parents to
vaccinate their children. (Stakeholder 5)
You know it’s right after the shot um in terms of kids asking about
‘I’ve heard it really hurts’ I think that you know that’s true of kids
anxieties with vaccines in general… we try to emphasize with all
shots you know that we’re gonna [sic] make it as comfortable as we
possibly can and it is self-limited… (Clinician 3)

Representative quote

Cancer Causes & Control
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Future risk uncertainty

Parallel healthcare example

Normalize the vaccine

Promotion via social media/TV

Strong provider recommendation

Personal experience

Greater provider education

Early age benefit

Anti-vaccine movement

Representative quote

I would say the concern that is the most challenging to address is I have some
families who have been on social media [sic] things about side effects as
related to the HPV vaccine, specifically, like chronic pain… (Clinician 8)
Text describing provider encounters with people who do not support vacThe most challenging is when they have a specific family member, like a
cination (of any kind)
mother-in-law or a spouse, who is strongly anti-vax. Where they know
they’re gonna [sic] get specific criticism for making a choice counter to that
family member… (Clinician 2)
Text describing how a provider messages the efficacy of receiving the vacWhy are we having to do this at this young of an age? But, it’s simple to
cine at a younger age, and how this could enhance immune response
answer – maybe tell them that, you know, studies have shown that the best
immunity occurs if you can complete the vaccine in this age group, so…
(Clinician 9)
Text describing a need for more comprehensive education on HPV, HPV
I think the most effective strategy would be doing some provider or clinician
vaccination, and the training necessary to facilitate it
education around making that presumptive bundle recommendation… And
then I think being able to also provide some training and education on what
to do when you get a hesitant parent. You know how to navigate that discussion. (Stakeholder 12)
Text describing a provider using personal experience to recommend the vac- I typically share that my children have gotten or will get it and that it’s our
cine, oftentimes regarding the vaccination of their own children
only vaccine that prevents cancer. (Clinician 10)
I think having a conversation with the families to make sure they understand
Text describing a provider recommending the vaccine at every visit type
with strong recommendation language and confidence
why we’re doing it and the importance of it – the clinician-to-family conversation. We also present it as part of the recommended immunization series,
but to us, it’s the same … It’s an important vaccine that we highly recommend … (Clinician 8)
Text describing the use of social media or television to promote messaging
I’ve seen education through media campaigns (specifically through TV ads on
for HPV vaccination
educating parents and kids about the vaccine). The real important thing I’ve
seen highlighted is that boys need to be vaccinated. I think there has been a
misconception that it should be just for girls, but boys and girls should be
vaccinated. (Stakeholder 4)
Text describing the use of normalizing the HPV vaccine along with other
I think if there’s three vaccines due, you recommend all three vaccines. You
recommended adolescent vaccines
don’t say ‘Your child needs the TDAP and the Meningococcal vaccine, and
I also want to talk to you about a very special recommendation for a very
special vaccine that I really strongly recommend, the HPV vaccine.’ That
makes the vaccine sound very weird and different. (Clinician 5)
Text describing a provider giving a similar example of preventive measures Well, just like with putting young women on birth control pills for acne, the
and study results that address the benefits and common concerns
studies show consistently that in their minds the two are so unrelated that
it just doesn’t make a difference. When kids decide to have sex, it’s not
because they have protection. (Clinician 2)
Text describing a provider warning parents that they cannot control for the
I know it’s because they just imagine that they’re raising their daughters that
risk of infection of HPV of their child’s future partner
there’s no way in the world they’d ever have pre-marital intercourse, then
I’ll often say ‘That’s great, but you have no control over who the person
they marry has … if they’ve ever had one partner before. (Clinician 2)

Definition

Social media and false information Text describing clinicians explaining encounters with parents who find false
information online

Theme

Table 4  External Messaging Themes around HPV Vaccination

Cancer Causes & Control

Text describing presenting the HPV vaccine as cancer prevention (framing)
Cancer prevention

Text describing tailoring messages based on gender
Sex-specific messaging

Sometimes in parents of boys, they’ve heard that it’s a cervical cancer vaccine, so you have to emphasize that that we’re protecting um the boys from
those head and neck cancers… (Clinician 3)
I think the concern about cancer and transmission rings home. (Clinician 7)

Definition
Theme

Table 4  (continued)

Representative quote
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Healthcare system‑related factors
Stakeholders were asked about HPV vaccination at the
organizational level. For most organizations, HPV vaccination had become more of a priority recently. However, it was
often in competition with other organizational commitments:
“Well, if I could say on a scale of 1 to 10, it’s not a 0 and
it’s not a 10 … maybe an 8 because it is publicly reported”
(Stakeholder 2).
Less than half of the clinicians we interviewed knew of
ongoing quality improvement initiatives to increase HPV
vaccine uptake within their organizations. Clinicians who
noted quality improvement initiatives frequently cited local
access expansion and clinic workflow measures as targets
for increasing HPV vaccine uptake. Expanding access to
the vaccine by offering it at venues outside the clinic was
one commonly cited measure with a clinician noting “We
also have started offering the HPV vaccine in our express
clinics. We have two express clinics in the community where
… they’re located at supermarkets” (Clinician 5). Changes
addressing vaccines during the check-in process and leveraging the electronic medical record (EMR) system were also
commonly employed to try to increase HPV vaccine uptake.
One example of this was a clinician who noted that checking
for vaccine receipt occurred at the time of any visit even outside of usual annual physicals—“If they’re in for any other
visit outside of a yearly physical, then the rooming process
includes checking the vaccine status for anybody even if it’s
not for their annual visit …” (Clinician 10).
Partnerships precipitated by stakeholder groups with clinicians were felt to be crucial at improving HPV vaccine
uptake. One stakeholder noted that “we have completed two
rounds of a quality improvement initiative working with
physicians not only in Minnesota but also in a five-state area
to improve administration of first-dose HPV before age 13
for both boys and girls in their practice. We’ve seen those
rates increase from 30 up to 70% as part of the second round
of the quality improvement that we have done” (Stakeholder
6). For organizations in which stakeholders described an
ongoing quality improvement initiative, the use of financial
incentives for patients who have received the HPV vaccine
was considered to result in high rates of success. One stakeholder noted that “we have member incentives in the form
of [gift cards] that we are giving out to members when they
get their full series of HPV vaccination” (Stakeholder 8).

Discussion
Our study identified themes around messaging and interventions involving HPV vaccine uptake commonly encountered
by clinicians and healthcare-related stakeholders practicing
in Minnesota. The most commonly encountered concern
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Text describing access and availability of the HPV vaccine

Access

Representative quote

Having the immunizations available (shelf life of vaccine, cost
to maintain the inventory)—if the vaccine is not available to
them = missed opportunity. Access to the vaccine. (Stakeholder 8)
Financial incentives
Text describing the use of media to advertise financial incentives to We have a member voucher, so we will actually give $100 to members
vaccinate for HPV
who qualify, who complete the HPV vaccination series. (Stakeholder
7)
Organizational priority to increase vaccine uptake Text describing a participant’s perception of their organization’s
Well, if I could say on a scale of 1 to 10, it’s not a 0 and it’s not a 10…
level of priority to increase HPV vaccination uptake
maybe an 8 because it is publicly reported. (Stakeholder 2)
Reporting of vaccination rates
Text describing the use of reporting a clinic or provider’s vaccination I think one strategy that is really important that Minnesota has done
rates as a way to increase uptake
is the Minnesota Community Measurement – they have added this as
a measure for providers to be aware that you are getting scored on
against your peers for this particular measure. (Stakeholder 4)
Well, we had to work hard to modify EPIC, which is our electronic
Leveraging the EMR
Text describing electronic medical record (EMR) prompts that
medical record system, to bring it up to date with the two-dose vacremind providers to communicate with patient/parent that they are
cine. And we’re currently struggling with EPIC to fix the problem
due to be vaccinated
of young adults who start the vaccine and then age out of 26. Like
the national recommendations we hold the that they who began the
series should completed. But EPIC currently doesn’t recommend it
for people 27 years or older even for the second and third doses…
(Clinician 5)
Maximize administration opportunities
Text describing increasing the number of venues in which the HPV We also have started offering the HPV vaccine in our express clinics.
vaccine is offered
We have two express clinics in the community where … they’re
located at supermarkets (Clinician 5)
If they’re in for any other visit outside of a yearly physical, then the
Clinic workflow and scheduling
Text describing specific process changes within a clinical venue
rooming process includes checking the vaccine status for anybody
that are undertaken to streamline discussing and administering the
even if it’s not for their annual visit… (Clinician 10)
vaccine
Utilize minnesota immunization information con- Text describing the use of MIIC data in various clinics or healthcare Unfortunately, all providers are not using MIIC. Not sure as to what
nection (MIIC) Data
systems
percent are not using it. When we just use MIIC, our vaccination
rates are very low compared to when we use Chart Review, they’re
much higher. Don’t know of anyone who has published on this.
Looking at the health plan data vs the MIIC data gives an idea of
how you’re doing. (Stakeholder 3)
Mandate vaccine
Text describing a participant suggesting that the vaccine should
Obviously, we would love for it to become a school mandated vaccine,
become mandatory
but we believe that’s outside our bailiwick… (Clinician 5)

Definition

Theme

Table 5  Healthcare system-related themes around HPV vaccination
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raised by adolescents’ parents about the HPV vaccine during clinic visits involved its impact on sexual activity. The
messaging strategy most consistently recommended among
interviewees was the promotion of the HPV vaccine as a
cancer prevention vaccine. Several clinicians in our study
described the benefit of framing the vaccine solely in terms
of its cancer prevention benefit. This insight is prescient
given that efforts in other states to evaluate barriers to HPV
vaccine uptake have shown that a lack of understanding
about the link between cancer and the HPV vaccine is common among parents of adolescents [9, 10]. The lack of prioritization of the HPV vaccine among healthcare systems and
other stakeholders within Minnesota was another important
finding from this study as many clinicians noted that they
were not involved with any direct quality improvement projects focused on raising HPV vaccine uptake rates in their
clinics. However, there seemed to be increasing awareness of
the importance of HPV vaccine administration, particularly
as measures are being taken to publicly report this data in
Minnesota. Increasing awareness of the benefits of increasing HPV vaccine uptake among healthcare organizations
operating within Minnesota would be a good starting point
for improving HPV vaccine uptake rates.
Additionally, concerns about misinformation related to
the impact of social media were common among both clinician and stakeholder interviewees. Also mentioned were
quality improvement initiatives and media campaigns that
utilize electronic media to counter misinformation and promote the benefits of the HPV vaccine. There is an emerging
literature around the possibility of utilizing social media to
better understand concerns related to the HPV vaccine [11].
Some studies have analyzed how the content of messages
posted on social media platforms drive varying levels of
engagement and the routes through which they link to sites
providing information about the HPV vaccine [11–13]. A
method to leverage social media platforms to directly reach
target populations who would benefit from receipt of the
HPV vaccine has also been examined [14]. Specific quality
improvement projects that incorporate electronic medical
records and other electronic or social media were mentioned
by several clinicians and stakeholders as a means to improve
HPV vaccine uptake rates. Our study has helped to highlight these for future interventions that could be deployed
to improve HPV vaccine uptake rates in Minnesota and
elsewhere.
Our sampling strategy for identifying interviewees is
a potential limitation of this study given that many of our
interviewees were drawn from Minnesota’s largest metropolitan areas, potentially decreasing the viewpoints of residents
of more rural parts of the state. However, we worked in conjunction with the Minnesota Department of Health to identify areas of lower vaccine uptake within Minnesota and did
specific outreach in those counties of the state found to have

HPV vaccine uptake rates that were below the statewide
average. An additional limitation of our study was its small
number of interviewees, which could reduce the perceived
number of factors identified in our study as being significant
to a larger group of clinicians or stakeholders (e.g., vaccine
perception among specific population subgroups). However,
our sampling methods allowed for outreach to interviewees
over a broad geographic area within Minnesota, resulting in
capture of a diverse breadth of attitudes around HPV vaccination. This can help us to build upon prior studies on
this topic in Minnesota that utilized a narrower scope of
recruitment [15, 16]. The results will allow for the design of
more targeted qualitative and quantitative studies to evaluate factors that may be more pertinent to our state, such as
the effect of including HPV vaccination as a community
measure.

Conclusion
In conclusion, clinicians and stakeholders working within
Minnesota highlighted consistent messages expressed by
patients and their family members that were often grounded
in a lack of knowledge about the HPV vaccine or misinformation. These factors could contribute to hesitancy to
receive the HPV vaccine and account for issues with increasing HPV vaccine uptake to the Healthy People 2020 target
of 80% completion of the vaccine series among adolescents.
Messaging methods to counter misinformation were also
described as were techniques involving quality improvement projects being implemented in some clinics as previously described. These included providing a strong provider
recommendation to receive the HPV vaccine, focusing on
cancer prevention benefits of the vaccine, normalizing the
vaccine as part of a standard set of immunizations, leveraging clinic workflow and EMR systems, using social media
campaigns to promote awareness and factual information
about the vaccine, and utilizing novel strategies such as
financial incentives to promote vaccine uptake. The information gleaned from this study will be informative for designing clinical interventions at a larger scale to help increase
HPV vaccine uptake. While this study was conducted within
Minnesota, the lessons learned can be applied more generally to other communities outside the state.
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